Evidence map›Paper›PMID 33780275›Full record

ArticleThe Journal of urology2021

Active Surveillance for Risk Stratification of All Small Renal Masses Lacking Predefined Clinical Criteria for Intervention.

Arun R Menon, Ahmed A Hussein, Kristopher M Attwood, Tashionna White, Gaybrielle James, Bo Xu, Michael Petroziello, Charles L Roche, Eric C Kauffman

Open access · greenAbstract read
In one paragraph

Article in The Journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Development of modified multi-parametric CT algorithms for diagnosing clear-cell renal cell carcinoma in small solid renal masses.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Article
  7. The evolving management of small renal masses.Nature reviews. Urology · 2024
    Review
  8. Accuracy, safety, and diagnostic prediction of percutaneous renal mass biopsy and subsequent changes in treatment.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Arun R MenonDepartment of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Ahmed A HusseinDepartment of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Kristopher M AttwoodDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Tashionna WhiteDepartment of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Gaybrielle JamesDepartment of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Bo XuDepartment of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Michael PetrozielloDepartment of Diagnostic Radiology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Charles L RocheDepartment of Diagnostic Radiology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Eric C KauffmanDepartment of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Roswell Park Comprehensive Cancer Center · USCairo University · EG

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
NCI NIH HHS P30 CA016056
6 · The paper itself

Abstract

purposeDespite general indolence of small renal masses and no known adversity from treatment delays, broad usage of active surveillance as a means to risk-stratify patients with small renal masses for more selective treatment has not been studied. We describe outcomes for a novel approach in which active surveillance was recommended to all patients with small renal masses lacking predefined progression criteria for intervention. MATERIALS AND

methodsAll nondialysis dependent patients with nonmetastatic small renal masses seen by 1 urologist at a comprehensive cancer center during January 2013-September 2017 were managed with active surveillance if standardized progression criteria for intervention were absent, with delayed intervention recommended only upon progression criteria for intervention development. Progression criteria for intervention were defined prospectively as small renal mass-related symptoms, unfavorable histology, cT3a stage or either of the following without benign neoplastic biopsy histology: longest tumor diameter >4 cm; growth rate >5 mm/year for longest tumor diameter ≤3 cm or >3 mm/year for longest tumor diameter >3 cm.

resultsIn all, 96% (123/128) of patients with small renal masses lacked progression criteria for intervention at presentation and underwent active surveillance. With median/mean 31/34 months followup, none developed metastasis and 30% (37/123) developed progression criteria for intervention, 78% (29/37) of whom underwent delayed intervention. One (1%) patient crossed over to delayed intervention without progression criteria for intervention. Three-year progression criteria for intervention-free and delayed intervention-free rates were 72% and 75%, respectively. Delayed intervention resections were enriched (62%) for pT3 and/or nuclear grade 3-4 malignant pathology, with no benign resections.

conclusionsActive surveillance using predefined progression criteria for intervention in otherwise unselected patients with small renal masses allows intervention to be focused on at-risk small renal masses with common adverse pathology, avoiding treatment for most patients with small renal masses. Long-term delayed intervention and oncologic safety require study.

Indexed as

Risk AssessmentWatchful WaitingBiopsyDisease ProgressionFemaleHumansKidney NeoplasmsMaleMiddle AgedRetrospective StudiesTime-to-Treatmentcarcinoma, renal cell; disease progressionkidney neoplasmsneoplasm metastasis

Identifiers

PMID33780275
PMCPMC9036570
OpenAlexW3143113092

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.